Skip to main content

1. ToxGenSolutions BV identified a 9 miR periferal profile that can identify individuals at risk for acquiring late-onset Alzheimer’s Disease years in advance

28.10.2022

This proposal addresses the objective to drive the development of cutting-edge biomarkers and to explore novel diagnostic technologies.

The ultimate goal of our program is to make diagnosis of late-onset Alzheimer’s Disease (AD):

  1. faster by turning the months/years it takes for the current diagnostic approach into hours,
  2. cheaper by eliminating expensive scans (e.g., €2,000-€2,500/$3,000-$4,500 for PET scans),
  3. more accurate in the prodromal phase of the disease with currently 50% of individuals diagnosed with mild cognitive impairment (MCI) not developing dementia,
  4. less invasive by replacing CSF sampling with blood sampling (urine as an option).

Our work-hypothesis: Individuals at risk for progressing into AD must be identified early if future drugs (once available) are to have any effect on the quality of life. Thus, novel biomarkers should reflect processes that are in transition from normal physiology into AD related pathology before neurons start to die off and the brain volume shrinks.

Next step: The prognostic profile is currently being validated with the support from the EU EuroStars programme. The product will be a biosensor device providing results within 3 hours after the blood/urine sample was taken, with a 90% accuracy according to the data that emerged from a pilot study.

Outreach: ToxGenSolutions is reaching out to investors and companies active in the field of diagnostics and drug development with the purpose of setting up commercial collaborations.

TOXGENSOLUTIONS REPRESENTED THE INTERREG. PROJECT ”MEMORIES” DURING THE 29th ALZHEIMER’S EUROPE CONGRESS IN THE HAGUE.

ToxGenSolutions presented a poster showing the approach adopted by the Interreg. project to develop a test for diagnosis of Alzheimer’s disease before it strikes (29th AEC_poster_PO.20.11). The congress was characterized by a high representation of technologies and technological developments that focusses on monitoring the patients. Presentations on scientific progress were limited, and focussing on the clinical phase of disease: ”Looking at Alzheimer’s through the peephole of dementia” as one of the speakers stated. Beside our poster, there was little, if at all, focus on the impact of environmental factors on induction and development of Alzheimer’s.  

INTERREG. PROJECT ”HERINNERINGEN”: SYMPOSIUM ‘STOP ALZHEIMER’ on Monday December 16, 2019

The INTERREG Vlaanderen-Nederland project ”Herinneringen” (”Memories”) organises its 2019 Symposium STOP ALZHEIMER on Monday December 16 in the wonderful ‘Promotiezaal’ of the Katholieke Universiteit Leuven (Naamsestraat 22, 3000 Leuven).
The programme offers science (in English) and more down-to-earth information (in Dutch) targeting patients, patient organizations and healthcare workers. There will be space for questions, discussion and networking in a relaxed atmosphere.

THE INTERREG. PROJECT HERINNERINGEN (‘MEMORIES’) 2018 SYMPOSIUM ON EARLY BIOMARKERS FOR SPORADIC ALZHEIMERS

27.11.2018 BY TOXGENSOLUTIONS BV
Many thanks to the participants, and especially the speakers: Catherine Verfaillie (KULeuven (host)), Francesca Pistollato (EURLECVAM (invited speaker)), Annemie Ribbens (icometrix), Sebastiaan Engelborghs (UAntwerpen), Gerard Griffioen (reMYND), Jacco Briede and Rob Schlooz (UMaastricht) and Erwin L Roggen (ToxGenSolutions).

The presentations will soon be available on toxgensolutions.eu.

TOXGENSOLUTIONS BV INVITES APPLICATIONS FOR A POSITION AS EXPERIENCED RESEARCHER, STARTING JANUARY 1, 2019.

16.11.2018 BY TOXGENSOLUTIONS BV

POSITION FOR AN EXPERIENCED RESEARCHER

ToxGenSolutions BV invites applications for a position as experienced researcher, starting January 1, 2019.

ToxGenSolutions BV invites applications for a position as experienced researcher, starting January 1, 2019.

You see you self as a researcher at a spin-off company based at the University of Maastricht with an ambition to expand. The research field is Neurodegeneration of the human brain, with focus on Alzheimer’s Disease (AD).

The successful candidate will participate in an AD project supported by EU Interreg. Vlaanderen – Nederland, het Nederlands Ministerie van Economische Zaken, de Provincie Nederlands Limburg, Vlaams Agentschao Innoveren en Ondernemen (VLAIO) and the Provinces of Antwerpen and Vlaams Brabant.

RESPONSIBILITIES AND TASKS:

  • Experimental planning of the project, problem solving and assuring compliance with the timelines of the project.
  • Laboratory work within the field of microRNA detection.
  • Performance of differential (epi-)genomics and pathway analyses.
  • Handling and reporting of experimental data.
  • Preparing microRNA profiles with diagnostic value for the market.

QUALIFICATIONS:
Applicants should have a PhD degree in (epi)genomics or equivalent with several years of experience.

THE PROFILE OF THE IDEAL CANDIDATE:

  • You have experience with and enjoy laboratory work.
  • You have hands-on experience with state-of-the-art (epi-)genomics technologies.
  • Experience in bioinformatics will be considered an advantage.
  • You communicate fluently in English.
  • You can work with deadlines and pressure.
  • You are flexible, enthusiastic and responsible, with team spirit and excellent collaboration skills.

WE OFFER:
ToxGenSolutions BV offers a competitive scientific environment with the ambition to build a self-sustainable company applying front-edge non-animal toxicogenomics approaches on human health problems to provide the customer with genetic biomarker fingerprints for application in novel more accurate methods for diagnosis, novel tools for follow-up of disease progression or response to treatment in humans, and novel drug development.

SALARY AND TERMS OF EMPLOYMENT:
The appointment will be based on the current wage scales that are applied by the University of Maastricht. The position is for two years.

FURTHER INFORMATION:
For additional information about the position, please contact Erwin L Roggen (erwin.roggen@toxgensolutions.eu).

You can read more about ToxGenSolutions BV on www.toxgensolutions.eu.

APPLICATION PROCEDURE:
Please submit your application no later than December 10, 2018 (Local time). Applications and enclosures received after the deadline will not be considered.

Applications must be submitted as one PDF file containing all your materials in English. The file must include:

  • Application (cover letter)
  • CV
  • Diploma (MSc)

All interested candidates irrespective of age, gender, disability, race, religion or ethnic background are encouraged to apply.


YOU ARE HEREBY CORDIALLY INVITED TO THE FIRST ANNUAL MEETING ON NOVEMBER 23TH 2018 IN BUILDING ON1 AT THE KATHOLIEKE UNIVERSITY LEUVEN (HERESTRAAT 49, LEUVEN).

23.10.2018 BY TOXGENSOLUTIONS BV

The project ‘Herinneringen’ (‘Memories’) is about to finish the first year of its search for a cost-effective and minimally invasive method allowing for accurate diagnosis of (sporadic) Alzheimer’s disease (AD) before significant damage to the brain has occurred.

You are hereby cordially invited to the first annual meeting on November 23th 2018 in building ON1 at the katholieke University Leuven (Herestraat 49, Leuven). Participation is free but registrations via the project web site (Menu, Contact) is required for practical reasons.

The program can be downloaded from the same web site. Francesca Pistollato from the European Reference Laboratory – European Center for validation of Alternative methods to Animal Testing (EURL-ECVAM) will address the current challenges met by traditional AD research, and the need for the paradigm shift that forms the basis of the project ‘‘Herinneringen’ (‘Memories’).

The project partners will present an overview of the different activities that are planned to meet the final goal, and progress will be reported where relevant. Special attention will be given to (i) the selection of the external risk factors for sporadic AD; (ii) the cell-based methods for identification of molecular and cellular processes that may be involved in the onset and early development of AD-related processes; (iii) the strategies to scientifically validated the human relevance of the identified potential biomarkers. See you November 23th.

  • 1
  • 2